Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

1. Twelves, C.
2. Cortés, J.
3. O'Shaughnessy, J.
4. Awada, A.
5. Perez, E.A.
6. Im, S.–A.
7. Gómez-Pardo, P.
8. Schwartzberg, L.S.
9. Diéras, V.
10. Yardley, D.A.
11. Potter, D.A.
12. Mailliez, A.
13. Moreno-Aspitia, A.
14. Ahn, J.-S.
15. Zhao, C.
16. Hoch, U.
17. Tagliaferri, M.
18. Hannah, A.L.
19. Rugo, H.S.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.EJCA.2017.02.011 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus